BioMidwest
Filter News
Found 82,067 articles
-
Curium Enrolls First Prostate Cancer Patients in its Phase 3 SOLAR Trials
4/23/2024
Curium, a world leader in nuclear medicine, announced today that it has successfully enrolled and scanned patients in its SOLAR clinical trials.
-
Neuronoff Announces Safety and Functionality Success in First-in-Human Trial of Injectrode for Minimally Invasive Chronic Pain Relief (LIFE study)
4/23/2024
Neuronoff, Inc. announced a significant milestone in its mission to transform chronic pain management.
-
Endevica Bio drug candidate shows success in weight loss in new study
4/23/2024
Endevica Bio, a company developing first-in-class peptide drug candidates, announced its novel weight-loss treatment was successful in a recent diet-induced obesity (DIO) rat study.
-
Electromed, Inc. Schedules its Third Quarter Fiscal 2024 Financial Results Conference Call for May 7, 2024 at 5:00 p.m. ET
4/23/2024
Electromed, Inc. today announced that it will issue its financial results press release for the fiscal 2024 third quarter ended March 31, 2024, on May 7, 2024 after the close of the stock market.
-
Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024
4/22/2024
Catalyst Pharmaceuticals, Inc. announced that it will release its first quarter 2024 financial results after the market close on Wednesday, May 8, 2024.
-
Kraig Biocraft Laboratories Successfully Completes Recombinant Cocoon Production From Spring Trials
4/22/2024
Kraig Biocraft Laboratories, Inc., announces what it considers to be a major milestone. The Company has completed rearing of the first generation of its new BAM-1 parental strains as part of its spring production trial.
-
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K
4/22/2024
Exicure, Inc., announced it received a notice of non-compliance from Nasdaq Stock Market LLC on April 17, 2024 notifying the Company that, as a result of the Company’s failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2023, the Company is not in compliance with Nasdaq Listing Rule 5250, which requires listed companies to timely file all periodic financial reports with the U.S.
-
OrthoPediatrics Corp. to Report First Quarter 2024 Financial Results on May 7, 2024
4/22/2024
OrthoPediatrics Corp., a company focused exclusively on advancing the field of pediatric orthopedics, announced that the Company is scheduled to release its first quarter 2024 financial results on Monday, May 6, 2024, after the market closes.
-
PharmaLogic announces opening of new state-of-the-art radiopharmaceutical production facility in Cincinnati
4/22/2024
PharmaLogic Holdings Corp. announced the opening of its new radiopharmaceutical production and research facility in Cincinnati, Ohio.
-
Abeona Therapeutics Provides Regulatory Update on Pz-cel
4/22/2024
Abeona Therapeutics Inc. announced a regulatory update for prademagene zamikeracel.
-
Zeus Names Chief Technology Officer
4/22/2024
Zeus, a world leader in polymer extrusion and catheter manufacturing, announces the appointment of Suresh Sainath as Chief Technology Officer.
-
CIRCA SCIENTIFIC to Attend Heart Rhythm 2024
4/22/2024
CIRCA Scientific, Inc., a pioneer in the development of esophageal temperature monitoring, will be attending Heart Rhythm 2024 to showcase the company's latest technologies for Cardiac Electrophysiology.
-
Medpace Holdings, Inc. Reports First Quarter 2024 Results
4/22/2024
Medpace Holdings, Inc. announced financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Results Revenue for the three months ended March 31, 2024 increased 17.7% to $511.0 million, compared to $434.1 million for the comparable prior-year period.
-
Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025Trial's lower-than-expected event rate suggests improved survival outcomes
4/22/2024
Panbela Therapeutics, Inc. today announced that the interim data analysis for its ongoing ASPIRE trial is now expected to be available as soon as Q1 2025.
-
Artivion Announces Release Date and Teleconference Call Details for First Quarter 2024 Financial Results
4/22/2024
Artivion, Inc. announced that first quarter 2024 financial results will be released on Monday, May 6, 2024 after the market closes.
-
Clarametyx Biosciences Expands Team Expertise to Accelerate Pipeline Momentum
4/22/2024
Clarametyx Biosciences Inc today announced it has appointed two leaders to further build the company’s continued pipeline momentum.
-
Stereotaxis to Report First Quarter 2024 Financial Results on May 13, 2024
4/22/2024
Stereotaxis today announced that it will release financial results for its 2024 first quarter on Monday, May 13, 2024 at the close of the U.S. financial markets.
-
Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting
4/22/2024
Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”) today announced that Daniel Su, M.D. will deliver a paper presentation on oral APX3330 at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to be held May 5-9, 2024 in Seattle, Washington.
-
Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
4/19/2024
Oragenics, Inc., a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, announced that it received a notice from the NYSE American LLC dated April 18, 2024, notifying the Company that it is no longer in compliance with NYSE American continued listing standards.
-
Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1
4/19/2024
Surmodics, Inc today announced that second quarter of fiscal year 2024 financial results will be released before the market opens on Wednesday, May 1.